Holmes Biopharma, Inc.: Initiates Broker Relations Program
January 23 2008 - 12:22PM
Marketwired
SCOTTSDALE, ARIZONA is pleased to announce that it has retained
the services of Newport Capital Consultants, Inc., a California
based consulting firm engaged in the provision of broker relations
consulting expertise to private and public companies. Mr. Bryant,
President, who has over 40 years of experience in the investment
banking services industry, and his team of consultants are
respected Associate Members of the National Investment Bankers
Association (NIBA), as well as members of the Southern California
Investment Association (SCIA). Newport Capital Consultants has
advanced over 50 companies from the OTC Board to the AMEX and the
NYSE. Many of these companies received significant funding from
investors introduced by Newport Capital Consultants.
"The addition of Newport Capital Consultants will introduce
Holmes Biopharma to a broader network of Investment bankers through
their well established network,"
stated John Metcalfe, President and CEO.
About Holmes:
Holmes Biopharma, Inc. is a contract research organization
focused on providing integrated and cost effective clinical
development services to the pharmaceutical industry and is actively
involved in developing new drugs and drug delivery systems.
Currently, clinics operate in Omaha, Nebraska USA, Toronto, Canada.
and Kiev, Ukraine, Eastern Europe. For more information about the
company please visit our website at www.holmesbiopharma.com.
On behalf of the Board of Directors
John F. Metcalfe, President, CEO
Certain statements in this press release constitute "forward
looking statements" within the meaning of the United States
Securities Legislation. The Company's actual results could differ
from those in the forward-looking statements. Do not construe this
information as investment advice. This is not a solicitation to buy
or sell securities. This does not purport to be a complete analysis
of the Company. Investing in securities is speculative and carries
a high degree of risk. Past performance does not guarantee future
results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All
information contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks
are not limited to quarterly fluctuations in results or the
companies' management of growth and competition. Other risks are
detailed in the Company's SEC filings. Actual results may differ
materially from such information set forth herein.
Contacts: Holmes Biopharma, Inc. John F. Metcalfe President, CEO
1-800-778-4990 Email: ir@holmesbiopharma.com Website:
www.holmesbiopharma.com
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Aug 2023 to Aug 2024